@article{JTD21800,
author = {Wen-Chien Cheng and Bing-Ru Wu and Wei-Chih Liao and Chih-Yu Chen and Wei-Chun Chen and Te-Chun Hsia and Chih-Yen Tu and Chia-Hung Chen and Wu-Huei Hsu},
title = {Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: a real-life study},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {6},
year = {2018},
keywords = {},
abstract = {Background: Long-acting muscarinic antagonist (LAMA) tiotropium improved lung function and reduced risks of exacerbation when added on to inhaled corticosteroids (ICS) with or without long-acting B2 agonists (LABAs) in patients with uncontrolled asthma. However, studies predicting the effectiveness of tiotropium based on patients’ clinical characteristics were limited.
Methods: We conducted this retrospective study at a single medical center from July 2016 to July 2017, and used asthma control test (ACT) to evaluate the effectiveness of tiotropium add-on therapy in patients with uncontrolled asthma. The effectiveness was shown by an increase in ACT score from baseline of 3 or greater after 3 months of tiotropium add-on therapy.
Results: Patients with uncontrolled asthma despite the use of low- or medium- to high-dose of ICS plus LABA (n=160) were analyzed. Among patients having good response (n=112, ACT score increased ≥3 points) to tiotropium (TGR group) and patients having poor response (n=48, ACT increased 430 µg/L and eosinophil count >0.6×109/L had a negative impact on response to tiotropium. Multivariate logistic regression analysis demonstrated that the independent factor of poor response to tiotropium was high serum IgE level >430 µg/L.
Conclusions: Tiotropium add-on therapy in patients with uncontrolled asthma was effective. However, patients with serum total IgE level >430 µg/L were less likely to benefit from tiotropium.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/21800}
}